SSTR1

Somatostatin receptor type 1 · P30872 · SSTR1 on Sugi Atlas →

33,480 patent compounds predicted against SSTR1, 20,231 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Somatostatin Receptor Ligand (SCHEMBL1164198)	0.69	13/20
Somatostatin Receptor Ligand (SCHEMBL1164024)	0.78	12/20
Somatostatin Receptor Ligand (SCHEMBL1237935)	0.65	12/20
Somatostatin Receptor Ligand (SCHEMBL8482)	0.83	11/20
SCHEMBL618829	0.50	11/20
Depreotide (SCHEMBL456503)	0.79	10/20
Somatostatin Receptor Ligand (SCHEMBL1163712)	0.79	9/20
SCHEMBL622154	0.48	9/20
SCHEMBL621689	0.46	9/20
SCHEMBL618828	0.44	9/20
SCHEMBL619418	0.44	9/20
SCHEMBL939678	0.33	9/20
SCHEMBL939679	0.33	9/20
SCHEMBL620781	0.44	8/20
SCHEMBL620949	0.44	8/20
SCHEMBL621314	0.44	8/20
Somatostatin Receptor Ligand (SCHEMBL670990)	0.60	7/20
SCHEMBL414621	0.57	6/20
SCHEMBL181078	0.52	6/20
SCHEMBL414620	0.47	6/20

Clinical trials — most relevant to SSTR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors	PHASE4	RECRUITING
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)	PHASE3	RECRUITING
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer	PHASE3	RECRUITING
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide	PHASE1/PHASE2	RECRUITING
Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors	PHASE1/PHASE2	COMPLETED
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors	PHASE1/PHASE2	RECRUITING
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer	PHASE2	COMPLETED
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	PHASE1/PHASE2	RECRUITING
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours	PHASE2	RECRUITING
Pasireotide LAR in Severe Polycystic Liver Disease	PHASE2	COMPLETED
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor	PHASE2	RECRUITING
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake	PHASE2	RECRUITING
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).	PHASE1/PHASE2	RECRUITING
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors	PHASE1/PHASE2	COMPLETED
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy	PHASE1/PHASE2	RECRUITING
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression	PHASE2	COMPLETED
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours	PHASE2	UNKNOWN
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer	PHASE2	COMPLETED
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression	PHASE2	UNKNOWN
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer	PHASE2	COMPLETED
TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets	PHASE2	COMPLETED
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors	PHASE1	RECRUITING
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers	PHASE1	RECRUITING
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms	EARLY_PHASE1	COMPLETED
Observational Study on GEP-and Pulm-NET Treated at FPG	nan	RECRUITING
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia	nan	NO_LONGER_AVAILABLE
Molecular and Whole-body MR Imaging in Lymphomas	nan	COMPLETED
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx	nan	APPROVED_FOR_MARKETING
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)	nan	NOT_YET_RECRUITING
Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SSTR1 binder may also engage these)

Protein	Name	Similarity
Q49LX5	—	1.000	Q49LX5 →
P30873	—	1.000	P30873 →
P28646	—	1.000	P28646 →
P30937	—	0.984	P30937 →
P49660	—	0.979	P49660 →
SSTR4	Somatostatin receptor type 4	0.979	landscape →
F1MV99	—	0.978	F1MV99 →
P30938	—	0.978	P30938 →
O08858	—	0.974	O08858 →
P30680	—	0.974	P30680 →
SSTR5	Somatostatin receptor type 5	0.971	landscape →
Q49LX6	—	0.968	Q49LX6 →
P34994	—	0.968	P34994 →
P30875	—	0.968	P30875 →
Q5D0K2	—	0.966	Q5D0K2 →
SSTR2	Somatostatin receptor type 2	0.965	landscape →
O97772	—	0.965	O97772 →
O42179	—	0.964	O42179 →
P34993	—	0.964	P34993 →
P48146	—	0.960	P48146 →
P33533	—	0.960	P33533 →
Q56UD9	—	0.959	Q56UD9 →
P30551	—	0.959	P30551 →
SSTR3	Somatostatin receptor type 3	0.958	landscape →
P32300	—	0.958	P32300 →
P33534	—	0.958	P33534 →
P42866	—	0.958	P42866 →
P34975	—	0.958	P34975 →
P49681	—	0.958	P49681 →
Q5IS84	—	0.957	Q5IS84 →